4 Blockbuster Drugs Whose Sales Could Easily Double
These drugs are already generating -- or on pace to generate -- more than $1 billion in annual sales, yet they're capable of so much more.
Better Buy Now: Medivation Inc vs Jazz Pharmaceuticals
These two mid-cap healthcare companies have been stellar long-term investments, but which company is the better buy today?
3 Cancer Companies to Watch Closely in 2016
These biotech companies should find out if their cancer drugs can pass muster with the FDA next year.
J&J's Earnings May Be Good News for Bristol-Myers Squibb and Medivation
Slowing sales for two top-selling therapies may mean that competitors gained ground last month.
How This Biotech Stock Hopes to Become More Than a One Trick Pony
Medivation acquired a late stage breast cancer drug from BioMarin in August.